A REVIEW ON SLN-INCORPORATED TRANSDERMAL PATCHES FOR PCOS TREATMENT
AbstractPolycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder and a leading cause of anovulatory infertility in women of reproductive age. Conventional oral therapies, such as clomiphene citrate, are often limited by poor bioavailability, first-pass metabolism, systemic side effects, and reduced patient compliance. Recent advancements in nanotechnology have introduced solid lipid nanoparticles (SLNs) as promising drug carriers due to their biocompatibility, stability, and controlled drug release properties. This review focuses on the application of SLN-incorporated transdermal drug delivery systems (TDDS) for PCOS management. Transdermal patches offer advantages such as bypassing hepatic first-pass metabolism, sustained drug release, and improved patient compliance. The review also highlights skin structure, formulation strategies, and evaluation parameters relevant to TDDS. Overall, combining SLNs with transdermal patches presents a novel and effective approach to enhance therapeutic outcomes and minimize adverse effects in the treatment of PCOS.
Download